Artificial intelligence software developed by Pangea Biomed can predict the chances that a patient will respond to cancer treatment by looking at tumor histopathology images.

The company’s published study shows that its AI-powered Enlight-DP platform can predict cancer treatment response from histopathology slides.

Pangea Biomed, the company behind the world’s most advanced cancer response predictor, ENLIGHT, today announced that new findings establishing the efficacy of its novel ENLIGHT-DP platform have been published in Nature Cancer. The study, conducted in collaboration with researchers from the Australian National University and from the US National Cancer Institute, reveals that combining ENLIGHT with the DeepPT approach for inferring gene expression from H&E slide scans significantly advanced the ability to predict therapeutic responses across multiple cancer types and drugs from histopathology images.

Pangea Scientific Advisory Board Member, Dr. Lillian Siu was named President-Elect of the  American Association for Cancer Research Board for 2024-2025

Dr. Amar Drawid sat down with Tuvik Beker to discuss the evolution of precision medicine, the challenges in matching the right drugs to the right patient, and how Pangea uses AI to analyze expression data and gene interaction maps to select the most effective drugs for individual patients.

Brian Gormley talked with Tuvik Beker and other AI and oncology experts about how startups are using AI to accurately diagnose and treat cancer patients.

glBRCA pancreatic ductal adenocarcinoma (PDAC) has a favorable response to platinum/PARP inhibition. However, most patients develop resistance. Additional treatment options for this unique subpopulation are needed. We generated model systems in PDXs and an ex vivo system (EVOC) that faithfully recapitulate these specific clinical scenarios as a platform to investigate the mechanisms of resistance for further drug development. In this study, we aimed to recapitulate the glBRCA PDAC population spectrum of responses to platinum and PARPi therapy, to explore the genomic and clinical features that may lead to different responses, and to investigate the mechanisms of resistance.

Pangea announces its partnership with patient-centric advocacy organization FibroFighters to advance treatment for fibrolamellar carcinoma (FLC) patients.

Pangea will conduct ENLIGHT analyses for FibroFighters’ patients to suggest treatment avenues, compare recommended treatments to actual outcomes, and improve models for response prediction

The Sunday Times’ tech correspondent Danny Fortson brings on Ranit Aharonov to talk about this moment for artificial intelligence, studying the brain, Project Debater, neural networks, language’s AlphaGo moment, the big idea at Pangea, getting it into the hands of doctors and drug communities, the role of AI in this tool, the regulatory limits, and why she didn’t debate the AI she created.

Karen Jagoda brings on Tuvik Beker and Ranit Aharonov to talk about precision oncology and the understanding of gene interactions and vulnerability of tumors.

Pangea announced that Dr. Lillian L. Siu, MD, FASCO, an internationally-renowned cancer researcher, has joined its scientific advisory board as the company continues to increase patient benefits by 5x using precision oncology and its multi-cancer response predictor.

Pangea CTO, Ranit Aharonov sat down with Amit Chowdhry from Pulse 2.0 to discuss her background in technology, all things Pangea and more!

Pangea co-founder, Eyal Gottlieb, Ph.D., will be joining the #1 cancer center in the world, MD Anderson Cancer Center, as vice president for Research.

Pangea’s case report on the success of an ENLIGHT-matched treatment for a woman with rare liver cancer has been published in the Journal for ImmunoTherapy of Cancer (JITC).

The findings on Pangea’s ENLIGHT platform, which applies unsupervised learning techniques to transcriptomic data, are published in Med.

Pangea CEO discusses the impact that technology can have on society with David Leichner.

Tuvik Beker, CEO of Pangea Biomed, sat down to chat with Karen Jagoda about how the company is looking for more accurate biomarkers for oncology to determine better who might benefit from a specific drug.

In this edition of MASH (Marketing Advice for Startups in Healthcare), VSC sat down with Tuvik Beker, the CEO of Pangea Biomed, a startup building an algorithmic platform called ENLIGHT to democratize precision oncology.

Tel Aviv, Israel-headquartered Pangea has raised a total of $12 million in seed funding since it emerged from stealth mode in April. The funds come from angel investor Danny Tocatly and existing investor NFX.

Pangea Biomed, the biotech company behind ENLIGHT, the multi-cancer response predictor improving the effectiveness of precision oncology, announced $5M in additional funding reaching a total seed round of $12M.

Onconova Therapeutics on Thursday said it will collaborate with Pangea Biomed to identify biomarkers of response to Onconova’s cancer drug candidate rigosertib.

Onconova Therapeutics and Pangea Biomed collaborate to leverage Pangea’s ENLIGHT platform in identifying biomarkers of response to Onconova’s cancer drug candidate rigosertib.

The funding extension, which brings the total seed round to $12M, will advance Pangea’s goal to expand commercial partnerships and US operations.

Eytan Ruppin has won the ASBMB’s 2023 DeLano Award in Computational Biology.

AI, Precision Oncology, and Understanding Cancer (Pangea Biomed)

How to Start a Life Science Company in Israel and Raise Capital in Silicon Valley

Dr. Ranit Aharonov, Chief Technology Officer, Pangea Biomed was awarded the 2022 Women In AI Research award from VentureBeat.

Israeli company emerges from stealth with seed funding touting “the next revolution in precision oncology”, powered by its ENLIGHT platform, designed to predict responses to therapies for dozens of cancers.

Pangea Biomed Ltd. picked up $7 million in seed financing to fast-track the development of its multicancer, multitherapy response predictor ENLIGHT.

Pangea Biomed is a Tel Aviv-based precision oncology biotech company building the world’s most advanced multi-cancer response predictor.

Pangea Biomed Launches Multi-Cancer Response Predictor, Increasing cancer Patient Benefits from Precision Oncology by 5x.

Dr. Cohen will lead Pangea’s SAB as the company identifies the most impactful applications of ENLIGHT.

Published in bioRxiv, the study leverages Pangea Biomed’s ENLIGHT platform to develop a novel approach to precision cancer care that combines AI techniques and digital pathology, bypassing the need for expensive and time-consuming DNA and RNA sequencing

Showcasing ENLIGHT’s ability to improve both personalized oncology and clinical trial design.